13F Holdings
中文EN

ALDX Aldeyra Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1341235 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY55.7%
TTM EPS YoY57.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-45.3%
ROA-31.6%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets18.8%
Debt / equity0.00x
Current ratio5.45x
Interest coverage-21.39x

Cash quality & payout

Operating cash flow / net income1.00x
Accruals ratio-0.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$1.84M$3.48M$2.41M$4.30M$5.43M$8.51M$7.42M$14.63M
SG&A expense$2.30M$2.37M$1.14M$2.36M$2.57M$1.66M$3.00M$1.95M
Operating income-$4.14M-$5.85M-$3.55M-$6.67M-$8.00M-$10.17M-$10.43M-$16.58M
Interest expense$438$23$468,678$475,259$475,903$470,618$483,529$470,863
Net income-$3.76M-$5.45M-$3.45M-$6.46M-$7.69M-$9.77M-$9.93M-$15.81M
EBITDA-$3.98M-$5.78M-$3.48M-$6.60M-$7.94M-$10.11M-$10.37M-$16.51M
EPS (basic)-0.06-0.09-0.06—-0.13-0.16-0.17—
EPS (diluted)-0.06-0.09-0.06—-0.13-0.16-0.17—
Weighted avg. shares (diluted)60.35M60.32M60.32M—60.13M60.05M59.89M—
Balance sheet
Cash & equivalents$40.97M$45.09M$65.00M$70.04M$59.34M$41.24M$50.35M$54.53M
Short-term investments———$0$15.96M$40.68M$39.71M$46.62M
Current assets$42.92M$47.38M$66.27M$71.78M$77.46M$84.56M$92.73M$104.07M
PP&E, net$17,991$20,544—$0———$0
Total assets$43.38M$47.54M$66.48M$72.06M$77.80M$84.96M$93.20M$104.61M
Current liabilities$7.88M$9.66M$24.33M$27.81M$28.48M$29.53M$14.29M$18.60M
Short-term debt$0$0$15.30M$15.25M$15.20M$15.15M$0$31,372
Long-term debt——$0$0$0$0$15.10M$15.00M
Total debt——$15.30M$15.25M$15.20M$15.15M$15.10M$15.03M
Total liabilities$8.16M$9.66M$24.33M$27.81M$28.56M$29.67M$29.60M$33.60M
Shareholders' equity$35.22M$37.89M$42.16M$44.25M$49.24M$55.29M$63.60M$71.00M
Net debt——-$49.70M-$54.79M-$44.14M-$26.09M-$35.25M-$39.50M
Shares outstanding60.36M60.32M60.32M60.16M60.16M60.05M60.05M59.65M
Cash flow statement
Operating cash flow-$4.12M-$4.59M-$5.11M-$5.30M-$7.02M-$8.56M-$12.47M-$12.04M
Investing cash flow$0-$23,097$0$16.00M$25.00M-$554,126$7.29M-$1.56M
Financing cash flow$9,692-$15.30M$71,140$0$120,746$0$1.00M$7,779
Depreciation & amortization$154,712$70,706$66,599$65,116$63,683$62,282$60,912$64,373
Stock-based compensation$1.11M$1.64M-$987,554$1.09M$2.58M$196,564$2.22M$1.26M

Free plan shows the latest 8 periods; Pro shows all 55 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.